



Targeting Angiogenic Pathways and Combination Approaches

Guest Editors:

Prof. Dr. Patrycja Nowak-Sliwiska

Prof. Dr. Arjan Griffioen

Angiogenesis Laboratory,
Department of Medical Oncology,
Amsterdam UMC, Cancer Center
Amsterdam, 1081 HV Amsterdam,
The Netherlands

Deadline for manuscript
submissions:

closed (29 February 2024)

Message from the Guest Editors

The aim of this Special Issue is to draw attention to vascular targeting approaches and increase knowledge on the combination of this strategy with other cancer therapies, such as immune-, chemo-, radio- and photodynamic therapies.

The Special Issue aims to publish a collection of original research articles and reviews. Potential topics may include (but are not limited to):

- New strategies for targeting the tumor vasculature.
- Combination strategies of anti-angiogenic therapy and other anti-cancer approaches.
- Enhanced insight in the mechanisms of angiogenesis and anti-angiogenesis.
- In vitro, preclinical and clinical approaches of anti-angiogenesis and combination therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)